Results Participants and baseline characteristics Between July 2019 and October 2021, 1839 individuals were screened, with 1441 randomly assigned to oral semaglutide 3 mg ( n =361), 7 mg ( n =360) or 14 mg ( n =361) or sitagliptin 100 mg ( n =359)
Victoza (liraglutide): Daily GLP-1 agonist
They target the side effects of sharply reduced food intake: lean-muscle loss, low protein and fiber intake, micronutrient shortfalls, and gastrointestinal discomfort
Methods Experimental protocols Sixty C57BL/6J male mice (1820 g, 810 weeks, Changsheng Biotechnology Company, Liaoning, China) were housed and fed at the First Hospital of China Medical University, the Institute of Respiratory Disease, under quiet and controlled specific pathogen-free conditions